UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
ConditionAlzheimer Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50+
SponsorUniversity of Alabama at Birmingham
About this trial
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
Eligibility criteria
Qualifiers
None
Disqualifiers
Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
Inability or contraindication for undergoing MRI and/or PET imaging
Inability to participate in the imaging studies due to severity of dementia
Trial design
Treatments tested in this trial
- [C-11]PiB-PET/MRI
Treatment groups
160 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov